Mosedale M, Watkins P B
Institute for Drug Safety Sciences, University of North Carolina at Chapel Hill, Research Triangle Park, North Carolina, USA; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
Clin Pharmacol Ther. 2017 Apr;101(4):469-480. doi: 10.1002/cpt.564. Epub 2017 Jan 11.
Drug-induced liver injury (DILI) is a major public health problem. Intrinsic (dose-dependent) DILI associated with acetaminophen overdose is the number one cause of acute liver failure in the US. However, the most problematic type of DILI impacting drug development is idiosyncratic, occurring only very rarely among treated patients and often only after several weeks or months of treatment with the offending drug. Recent advances in our understanding of the pathogenesis of DILI suggest that three mechanisms may underlie most hepatocyte effects in response to both intrinsic and idiosyncratic DILI drugs: mitochondrial dysfunction, oxidative stress, and alterations in bile acid homeostasis. However, in some cases hepatocyte stress promotes an immune response that results in clinically important idiosyncratic DILI. This review discusses recent advances in our understanding of the pathogenesis of both intrinsic and idiosyncratic DILI as well as emerging tools and techniques that will likely improve DILI risk identification and management.
药物性肝损伤(DILI)是一个重大的公共卫生问题。与对乙酰氨基酚过量相关的内在性(剂量依赖性)DILI是美国急性肝衰竭的首要原因。然而,影响药物研发的最具问题的DILI类型是特异质性的,仅在极少数接受治疗的患者中发生,且通常仅在使用致病药物治疗数周或数月后才出现。我们对DILI发病机制认识的最新进展表明,三种机制可能是大多数肝细胞对内在性和特异质性DILI药物产生反应的基础:线粒体功能障碍、氧化应激和胆汁酸稳态改变。然而,在某些情况下,肝细胞应激会引发免疫反应,导致具有临床重要性的特异质性DILI。本综述讨论了我们对内在性和特异质性DILI发病机制认识的最新进展,以及可能改善DILI风险识别和管理的新兴工具和技术。